Cartazolate

Last updated
Cartazolate
Cartazolate.svg
Clinical data
Routes of
administration 		By mouth
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • Уthyl 4-(butylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C15H22N4O2
Molar mass 290.367 g·mol−1
3D model (JSmol)
  • O=C(C1=CN=C(N(CC)N=C2)C2=C1NCCCC)OCC

Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABAA receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. [1] [2] [3] [4] It is also known to act as an adenosine antagonist at the A1 and A2 subtypes and as a phosphodiesterase inhibitor. [5] [6] Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. [7] It was developed by a team at E.R. Squibb and Sons in the 1970s. [8]

See also

References

  1. ↑ Placheta P, Karobath M (March 1980). "In vitro modulation by SQ 20009 and SQ 65396 of GABA receptor binding in rat CNS membranes". European Journal of Pharmacology. 62 (2–3): 225–8. doi:10.1016/0014-2999(80)90281-2. PMID   6103810.
  2. ↑ Supavilai P, Karobath M (March 1981). "Action of pyrazolopyridines as modulators of [3H]flunitrazepam binding to the gaba/benzodiazepine receptor complex of the cerebellum". European Journal of Pharmacology. 70 (2): 183–93. doi:10.1016/0014-2999(81)90213-2. PMID   6114867.
  3. ↑ Leeb-Lundberg F, Snowman A, Olsen RW (May 1981). "Perturbation of benzodiazepine receptor binding by pyrazolopyridines involves picrotoxinin/barbiturate receptor sites". Journal of Neuroscience. 1 (5): 471–7. doi: 10.1523/JNEUROSCI.01-05-00471.1981 . PMC   6564167 . PMID   7050308.
  4. ↑ Bristow DR, Martin IL (March 1990). "Biochemical characterization of an isolated and functionally reconstituted gamma-aminobutyric acid/benzodiazepine receptor". Journal of Neurochemistry. 54 (3): 751–61. doi:10.1111/j.1471-4159.1990.tb02315.x. PMID   2154549. S2CID   25784613.
  5. ↑ Daly JW, Hong O, Padgett WL, Shamim MT, Jacobson KA, Ukena D (February 1988). "Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors". Biochemical Pharmacology . 37 (4): 655–64. doi:10.1016/0006-2952(88)90139-6. PMC   3445624 . PMID   2829919.
  6. ↑ Wachtel H (1982). "Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors". Psychopharmacology. 77 (4): 309–16. doi:10.1007/BF00432761. PMID   6182575. S2CID   10122417.
  7. ↑ O'Brien, Robert (1986). Receptor binding in drug research. New York: Dekker. p. 519. ISBN   0-8247-7548-1.
  8. ↑ US 3966746,Hoehn, Hans&Denzel, Theodor,"Amino derivatives of pyrazolopyridine carboxamides",published 1976-06-29, assigned to Squibb & Sons Inc.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.